Investor relations
Investing in a physiological signal that is already in the field.
SENTHORIS is raising a Pre-Series A round to complete the software platform, run early clinical validation and prepare the pivotal study. Materials are shared with qualified investors on request.
- Round
- Pre-Series A
- Status
- In progress
- Domicile
- EU · US C-Corp planned
- Access
- NDA data room
Why it works
- 01
The signal is established science
The pupillary light reflex is a mapped neural circuit with measurable parasympathetic and sympathetic components, studied in clinical literature since the 1980s.
- 02
The engineering problem is solved
Acquisition stability, motion and illumination robustness, calibration and edge inference were proven in continuous industrial operation — not in a lab.
- 03
Demand is demonstrated
A Tier-1 oil & gas enterprise deployed the hardware version and pays for it. The software platform carries that demand to standard cameras.
- 04
The path to regulation is framed
A Memorandum of Understanding with PPD™, the clinical research business of Thermo Fisher Scientific, frames the clinical programme toward FDA De Novo (SaMD).
Request the investor deck
Each request is reviewed by the founding team. Qualified investors receive the deck and, following an NDA, access to the data room.
Data room contents
- Investor deck
- Technical overview
- Clinical development plan
- Regulatory strategy
- Financial model & use of funds
- IP summary
- Corporate & cap table
- Field deployment records
Direct enquiries: admin@senthoris.us
This page is for information only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offering will be made only to eligible investors under applicable exemptions and definitive documentation. Forward-looking statements reflect current plans and are subject to risks and uncertainties.